Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. - Wikidata - wikimedia - TriplyDB

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

http://www.wikidata.org/entity/Q37733556

about

Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo Stem cell therapy for erectile dysfunction: a critical review.Neurotrophic Effect of Adipose Tissue-Derived Stem Cells on Erectile Function Recovery by Pigment Epithelium-Derived Factor Secretion in a Rat Model of Cavernous Nerve Injury Regenerative technology for future therapy of erectile dysfunction.Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats Periprostatic implantation of neural differentiated mesenchymal stem cells restores cavernous nerve injury-mediated erectile dysfunction Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy.ADMET considerations for phosphodiesterase-5 inhibitors.Direct androgen regulation of PDE5 gene or the lack thereof.PDE5 inhibitors: considerations for preference and long-term adherence.The Challenge of Erectile Dysfunction Management in the Young Man.CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.The Current Status of Stem-Cell Therapy in Erectile Dysfunction: A Review.The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction.Potential applications of low-energy shock waves in functional urology.Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model.Gaseotransmitters: new frontiers for translational science.Effects of Next-Generation Low-Energy Extracorporeal Shockwave Therapy on Erectile Dysfunction in an Animal Model of Diabetes.Rehabilitation of the cavernous smooth muscle in patients with organic erectile dysfunction.Transplantation of Human Urine-Derived Stem Cells Transfected with Pigment Epithelium-Derived Factor to Protect Erectile Function in a Rat Model of Cavernous Nerve Injury.Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction against upregulated cavernosal NADPH oxidase, protein kinase Cε, and endothelin system in diabetic rats.

P2860

Q34022454-A0F05462-8662-482B-A8FE-3154402D9143 Q35737480-C03DB647-4545-44D7-9393-93AB11E81398 Q36405336-6C3C8A31-E6A6-4DE5-9A94-058A9E061817 Q36450791-3EBC5679-3D57-4F28-B779-35E04754AA93 Q37037818-B5498771-C85D-4462-8D2C-CD32B369F0FB Q37060766-6850F9D4-5E91-48F3-A83D-D9C95FF5D093 Q37886153-E92FA8AD-70F1-441C-B139-59EF5230EA7D Q38024409-50C02946-C99B-41FC-871A-A96A76155834 Q38088930-93D732BF-4B8A-4C08-AF7B-84D90CB784E2 Q38122721-E9B3180D-56B4-43E4-A6C4-EFADE8400626 Q38631968-E11D01A3-A2CD-43CB-A7D9-740BF39619C7 Q38821274-9528A50C-74F7-47D2-A6C5-428B3585542A Q39067832-A8C4FDA2-1FB7-4839-B5B4-783EC04BE2C5 Q39143822-4F91FD28-07C3-41CE-8A1B-4B5DCC83E358 Q39428940-11EBF60D-8C7D-4946-9B58-EE14D86C7A34 Q41336279-0C4266D0-45A7-4075-BFE8-EFBC889C6585 Q42600835-914B9FF3-824B-47F4-9F6C-2838EBA3C4E2 Q45874863-BF64C0A0-499B-415D-A27C-112D77A2630B Q46308285-E3E48C59-0B8D-4727-9D5E-D414418F20B3 Q52875108-72CE8AC4-1409-46A7-8131-FECF8836EF6E Q54330771-9E7DF8EC-7819-4D01-959B-41BB6CBDE741

P2860

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

http://www.wikidata.org/entity/Q37733556

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

@en

type

label

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

@en

prefLabel

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

@en

P1433

Q37733556-B7A90454-8AD3-4AF1-89F5-1C6D028A5AE1

P1476

Q37733556-B62CF240-2A6D-46A1-8653-F1D682837E9C

P2093

Q37733556-50B6A789-2257-4877-A491-0C0F2D6F6056

Q37733556-6F3E7823-1D67-41E2-8A65-25560037C0EE

Q37733556-806E2225-7E46-4B59-80C3-395BC78A93DB

Q37733556-9D10EEB3-2BE5-4CAF-9861-99669A05519C

P2860

Q37733556-01B11D28-6755-4F76-B097-69F16217A869

Q37733556-042E8951-04AD-4710-AFDB-55845D4D0EE0

Q37733556-046E007C-7140-49DD-8472-B3F6E3555739

Q37733556-0E07437A-CBE6-4CD2-9972-96F691F73A40

Q37733556-0E9B8DEB-7D9C-4EFF-831F-1274A7F08384

Q37733556-18149BAB-7F6D-4BA9-A537-2E5F1A92318A

Q37733556-25C459AE-BA80-4F4D-8D0B-C1FD7455326E

Q37733556-26408E08-D8D0-4571-B73A-0DAA8AF2E185

Q37733556-292B0A31-3809-4821-8FE2-D8C964F465BB

Q37733556-29E66C71-4B3D-4B05-9150-E79D69DFD923

P304

Q37733556-1840B810-08F2-4A57-992B-FE901B09CB56

P31

Q37733556-8AB44F11-6BDB-4B81-87AE-28FDA6E85A52

P356

Q37733556-CE1F42EE-BE36-4DA1-85CB-ECA15790DD94

P407

Q37733556-CB88A62A-7830-4540-8EBB-B7768074D64A

P433

Q37733556-3B548B77-9B8B-4B20-AD33-B4AC57577016

P478

Q37733556-C5C086B0-9A54-4D4C-86C6-08A6FF5AC66B

P577

Q37733556-2D7ED9F8-3DB6-44BE-83DD-522F12A7992F

P5875

Q37733556-1657B050-F08E-43E8-9415-C7D4F93109FF

P698

Q37733556-CAB095DD-F3AD-498B-BED6-6592408F416F

P356

14656561003698131

P1433

Expert Opinion on Pharmacotherapy

P1476

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

@en

P2093

Christopher Keel

http://www.w3.org/2001/XMLSchema#string

Meghan Klavens

http://www.w3.org/2001/XMLSchema#string

Philip Dorsey

http://www.w3.org/2001/XMLSchema#string

Wayne J G Hellstrom

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats

Erectile dysfunction.

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks

Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.

Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial.

Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.

P304

1109-1122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656561003698131

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43200007

http://www.w3.org/2001/XMLSchema#string

P698

20402554

http://www.w3.org/2001/XMLSchema#string